AUSTRALIAN CLINICAL LABS LIMITED (ASX: ACL)
Health care · News and insights
Price unavailable
Latest ACL announcements
Announcement Insights
Australian Clinical Labs Completes Buy-Back Below Its Share Limit As Major Holders’ Disclosed Stakes Decline
Australian Clinical Labs completed its year-long on-market buy-back in November 2026, repurchasing about 9.3 million shares for approximately $22 million—less than half its authorised 19.5 million-share cap. In late October, Commonwealth Bank, KKR and related entities, and Allan Gray reported lower voting interests, with disclosed stakes falling from roughly 8.2–8.3% to 7.2% for the first two groups and from 17.80% to 16.71% for Allan Gray; those changes do not establish direct share sales.
Updated 11 Nov 2026, 08:56 AM Sydney time
Sources
Update - Notification of buy-back - ACLNotification regarding unquoted securities - ACLChange in substantial holdingChange in substantial holdingChange in substantial holding2026 AGM - Chair and CEO AddressesChange in substantial holding from CBA2026 AGM - Voting ResultsComments
2026-11-11 · Health care
ACL: $3.32 +2.15% · MC: $619M
Australian Clinical Labs’ final notification records that it bought back about 9.3 million shares for approximately $22 million, below the authorised maximum of 19.5 million shares. The on-market buy-back ran from November 2025 to November 2026 and was subject to the company’s capital position and other factors.
Updated 2026-11-11 08:53
Sources
Update - Notification of buy-back - ACLComments
2026-11-05 · Health care
ACL: $3.20 +0.95% · MC: $619M
Australian Clinical Labs converted 31,368 service rights into ordinary shares, with the conversion completed between late October and early November. The shares were already quoted on ASX, and the company reported 186.5 million ordinary shares on issue following the conversion.
Updated 2026-11-05 16:48
Sources
Notification regarding unquoted securities - ACLComments
2026-10-30 · Health care
ACL: $3.30 +1.85% · MC: $619M
Allan Gray Australia and related entities reported a reduced relevant interest in Australian Clinical Labs, with voting power down from 17.80% to 16.71% since its previous notice. The filing records a change in interests but does not establish that the reduction reflects direct share sales.
Updated 2026-10-30 17:35
Sources
Change in substantial holdingComments
2026-10-29 · Health care
ACL: $3.24 +2.86% · MC: $619M
The KKR Entities reported a reduction in their voting power in Australian Clinical Labs, from 8.21% to 7.20%. The notice refers to a separate filing for details of the changes in relevant interests.
Updated 2026-10-29 11:39
Sources
Change in substantial holdingComments
2026-10-28 · Health care
ACL: $3.15 +6.42% · MC: $619M
Australian Clinical Labs shares jumped about 7% to $3.17 in afternoon trading as shareholders approved all resolutions at the pathology provider’s annual meeting. The vote included the appointment of Deloitte as auditor, performance rights for chief executive Greg Horan and renewal of proportional takeover provisions.
Separate substantial-holder notices showed Commonwealth Bank of Australia’s voting power fell to about 7% from over 8%, while Superannuation and Investments HoldCo reported a similar decline. The notices describe overlapping relevant interests, including interests held through a superannuation trustee and a managed investment scheme; the supplied excerpts do not establish the transactions behind the changes.
Updated 2026-10-28 16:13
Sources
Change in substantial holding2026 AGM - Chair and CEO AddressesChange in substantial holding from CBA2026 AGM - Voting ResultsComments
Comments